HT PARP in vivo Pharmacodynamic ELISA Kit II
This product has been discontinuation and replaced by catalog # 4520B-096-K
HT PARP in vivo Pharmacodynamic ELISA Kit II Summary
• Pre-coated 96 well capture antibody plates
• High signal to noise ratio
• Detection sensitivity of 2 pg/mL of PAR
• Broad linear dynamic range to 1,000 pg/mL
• Reduced inter-assay variability
• Validated assay that measures drug action on PARP in both in vivo and in vitro settings
• 96 test size
What is the HT PARP In Vivo Pharmacodynamic ELISA Kit II.
Immobilized PAR monoclonal antibody in the wells of a 96-well plate captures cellular PAR and PAR attached to proteins. Incubation with a polyclonal PAR detecting antibody, followed by addition of a goat anti-rabbit IgG-HRP secondary and a chemiluminescent HRP substrate yields relative light units (RLU) that directly correlates with the amount of cellular PAR.
- Quantitation of PAR in peripheral blood mononuclear cells, tissue culture cells, and tumor lysates from different tissues, organs and xenografts.
- Monitoring the efficacy of PARP inhibitors on PAR formation in vivo.
- Verifying observations of enhanced cancer cell cytotoxicity arising from PARP inhibitor/anticancer drug combination therapy.
- Facilitating development of PARP and PARG targeted therapeutics.
• PAR Standard, 25 pg/µl
• WIL2-NS Cell Lysate Control Standard, Low
• WIL2-NS Cell Lysate Control Standard, Medium
• WIL2-NS Cell Lysate Control Standard, High
• PAR Polyclonal Detecting Antibody
• Goat anti-Rabbit IgG-HRP
• DNase I, 2 Units/µl
• PARP Sample Buffer
• PARP Cell Lysis Reagent
• 100X Magnesium Cation
• PARP Antibody Diluent
• 20% SDS
• Pre-coated white 96-stripwell plate and 5 sealers
• PARP PeroxyGlow A
• PARP PeroxyGlow B
For research use only. Not for diagnositic use.
Measurement of PAR Levels in Jurkat Cells. The HT PARP In Vivo Pharmacodynamic Assay II (Catalog # 4520-096-K) was used to measure poly (ADP-ribose) (PAR) levels in cellular extracts from untreated Jurkat human acute T cell leukemia cells, Jurkat cells treated with PJ34, a potent PARP inhibitor, for 1.5 hours, and in Jurkat cell extracts incubated for 30 minutes with PAR glycohydrolase (PARG), an enzyme that digests PAR.
Citations for HT PARP in vivo Pharmacodynamic ELISA Kit II
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
Citations: Showing 1 - 10
Filter your results:
Coupling of PARP1-mediated chromatin structural changes to transcriptional RNA polymerase II elongation and cotranscriptional splicing
Authors: EA Matveeva, QMH Al-Tinawi, EC Rouchka, YN Fondufe-Mi
Epigenetics Chromatin, 2019;12(1):15. 2019
PARP1 is a versatile factor in the regulation of mRNA stability and decay
Authors: EA Matveeva, LF Mathbout, YN Fondufe-Mi
Sci Rep, 2019;9(1):3722. 2019
Pharmacology of the ATM inhibitor AZD0156: potentiation of irradiation and olaparib responses pre-clinically
Authors: LC Riches, AG Trinidad, G Hughes, GN Jones, AM Hughes, AG Thomason, P Gavine, A Cui, S Ling, J Stott, R Clark, S Peel, P Gill, LM Goodwin, A Smith, KG Pike, B Barlaam, M Pass, MJ O'Connor, G Smith, EB Cadogan
Mol. Cancer Ther., 2019;0(0):. 2019
A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice
Authors: D Zhang, P Baldwin, AS Leal, S Carapelluc, S Sridhar, KT Liby
Theranostics, 2019;9(21):6224-6238. 2019
A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models
Authors: K Sun, K Mikule, Z Wang, G Poon, A Vaidyanath, G Smith, ZY Zhang, J Hanke, S Ramaswamy, J Wang
Oncotarget, 2018;9(98):37080-37096. 2018
Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.
Authors: Rodler E, Kurland B, Griffin M, Gralow J, Porter P, Yeh R, Gadi V, Guenthoer J, Beumer J, Korde L, Strychor S, Kiesel B, Linden H, Thompson J, Swisher E, Chai X, Shepherd S, Giranda V, Specht J
Clin Cancer Res, 2016;22(12):2855-64. 2016
Epstein-Barr Virus Oncoprotein LMP1 Mediates Epigenetic Changes in Host Gene Expression through PARP1.
Authors: Martin K, Lupey L, Tempera I
J Virol, 0;90(19):8520-30. 0
Requirements to assess feasibility of phase 0 trials during major abdominal surgery: variability of PARP activity.
Authors: Heitz F, du Bois A, Rochon J, Scheil-Bertram S, Hils R, Fisseler-Eckhoff A, Barinoff J, Kaub C, Harter P
Clin Cancer Res, 0;18(9):2632-7. 0
Base excision repair defects invoke hypersensitivity to PARP inhibition.
Authors: Horton J, Stefanick D, Prasad R, Gassman N, Kedar P, Wilson S
Mol Cancer Res, 0;12(8):1128-39. 0
Predicting enhanced cell killing through PARP inhibition.
Authors: Horton J, Wilson S
Mol Cancer Res, 0;11(1):13-8. 0
Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
Authors: Cardnell R, Feng Y, Diao L, Fan Y, Masrorpour F, Wang J, Shen Y, Mills G, Minna J, Heymach J, Byers L
Clin Cancer Res, 0;19(22):6322-8. 0
Global Transcriptome Analysis Reveals That Poly(ADP-Ribose) Polymerase 1 Regulates Gene Expression through EZH2.
Authors: Martin K, Cesaroni M, Denny M, Lupey L, Tempera I
Mol Cell Biol, 0;35(23):3934-44. 0
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.
Authors: Lee J, Hays J, Annunziata C, Noonan A, Minasian L, Zujewski J, Yu M, Gordon N, Ji J, Sissung T, Figg W, Azad N, Wood B, Doroshow J, Kohn E
J Natl Cancer Inst, 0;106(6):dju089. 0
Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer.
Authors: Karginova O, Siegel M, Van Swearingen A, Deal A, Adamo B, Sambade M, Bazyar S, Nikolaishvili-Feinberg N, Bash R, O'Neal S, Sandison K, Parker J, Santos C, Darr D, Zamboni W, Lee Y, Miller C, Anders C
Mol Cancer Ther, 0;14(4):920-30. 0
Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo.
Authors: Janzen D, Paik D, Rosales M, Yep B, Cheng D, Witte O, Kayadibi H, Ryan C, Jung M, Faull K, Memarzadeh S
Mol Cancer Ther, 0;12(12):2917-28. 0
Implementation of validated pharmacodynamic assays in multiple laboratories: challenges, successes, and limitations.
Authors: Kinders R, Ferry-Galow K, Wang L, Srivastava A, Ji J, Parchment R
Clin Cancer Res, 0;20(10):2578-86. 0
No product specific FAQs exist for this product, however you mayView all FAQs
Reviews for HT PARP in vivo Pharmacodynamic ELISA Kit II
There are currently no reviews for this product. Be the first to review HT PARP in vivo Pharmacodynamic ELISA Kit II and earn rewards!
Have you used HT PARP in vivo Pharmacodynamic ELISA Kit II?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image